Cowen analyst Eric Schmidt reiterated his Outperform rating and $494 price target on Biogen (NASDAQ: BIIB), with shares down nearly ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View

Baird Downgrades Biogen (BIIB) to Neutral; Diminished Growth ProspectsJuly 27, 2015 6:35 AM Biogen's (BIIB) Decline Seen as 'Overreaction' at Deutsche BankJuly 24, 2015 3:36 PM Biogen (BIIB) Worth a 'Hard Look' when Smoke Clears, Stifel SaysJuly 24, 2015 12:19 PM Streetinsider.com's Hot Lunchtime Reads 7/24: (BIIB) (FCAU) (CARA) (Z)July 24, 2015 12:11 PM Slowing Tecfidera Sales Increases Biogen's (BIIB) M&A Risk - Moody'sJuly 24, 2015 11:55 AM BMO Capital Downgrades Biogen (BIIB) to Market PerformJuly 24, 2015 11:42 AM Biogen (BIIB) Tops Q2 EPS by 12c; Cuts FY15 Revenue Growth, EPS OutlookJuly 24, 2015 6:50 AM Biogen Second Quarter 2015 Revenues Increase 7% to $2.6 BillionJuly 24, 2015 6:50 AM